Quarterly ResultMay 20, 2026, 05:03 PM
RetinalGenix Faces Going Concern Doubt; Q1 Net Loss $(0.59)M; CFO Resigns
AI Summary
RetinalGenix Technologies Inc. reported a net loss of $(590,489) for Q1 2026, with cash reserves dwindling to $180, leading to substantial doubt about its ability to continue as a going concern. The company disclosed it lacks adequate resources to fund operations beyond June 2026. Additionally, its CFO, M. Cory Zwerling, resigned in March 2026, shortly after his appointment. Despite these challenges, RetinalGenix is pursuing capital raising and anticipates launching its RetinalCam™ device in Q4 2026.
Key Highlights
- Substantial doubt about RetinalGenix's ability to continue as a going concern due to accumulated deficits and insufficient funds.
- Q1 2026 net loss was $(590,489), a slight increase from $(587,259) in Q1 2025.
- Cash balance at March 31, 2026, was $180, significantly down from $3,711 at March 31, 2025.
- Total current liabilities increased to $2,560,679 at March 31, 2026, from $2,319,968 at December 31, 2025.
- Accumulated deficit reached $(18,449,106) as of March 31, 2026.
- CFO M. Cory Zwerling resigned in March 2026, having been appointed in January 2026.
- The company raised $200,000 in May 2026 by selling 88,888 shares of common stock.
- RetinalCam™ device launch is anticipated in the fourth quarter of 2026.
Price Impact
More from RTGN